A randomized phase 3 study of ivonescimab plus chemotherapy versus pembrolizumab plus chemotherapy for the first-line treatment of metastatic non–small cell lung cancer: HARMONi-3.

Authors: Jianjun Zhang, Jun Cai, Hui Wang, Yan Yu, Joaquim Bosch-Barrera, Reyes Bernabé, Zoran Andric, Firas Benyamine Badin, Yusuke Okuma, Paul K. Paik, Jarushka Naidoo, Haralabos Kalofonos, Bo Wang, Robert M. Jotte, Nathan A. Pennell, Jonathan W. Riess, Deborah Blythe Doroshow, Makoto Nishio, Jorge Arturo Alatorre-Alexander, Shun Lu

Published: 2025-05-28

DOI: 10.1200/jco.2025.43.16_suppl.tps8664

Source: Full article

---

Abstract

TPS8664